Results 281 to 290 of about 149,070 (296)
Some of the next articles are maybe not open access.
TP53 or Not TP53: That Is the Question
Clinical Cancer Research, 2022Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine.
Steven D. Green, Joshua F. Zeidner
openaire +2 more sources
2018
The p53 transcription factor is mutated or inactivated in most cancers to circumvent its diverse tumor suppressive functions. p53 becomes activated downstream of a range of cellular stresses to induce diverse transcriptional programs. Canonically activation of acute DNA damage results in growth suppression by inducing cell cycle arrest to enable DNA ...
McDade, Simon, Fischer, Martin
openaire +3 more sources
The p53 transcription factor is mutated or inactivated in most cancers to circumvent its diverse tumor suppressive functions. p53 becomes activated downstream of a range of cellular stresses to induce diverse transcriptional programs. Canonically activation of acute DNA damage results in growth suppression by inducing cell cycle arrest to enable DNA ...
McDade, Simon, Fischer, Martin
openaire +3 more sources
TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy
2019The tumor suppressor gene Tp53 encodes p53, a pivotal transcription factor with a broad target gene repertoire. Induction and stabilization of p53 during DNA damage and oncogene activation function to induce cell cycle arrest, apoptosis, or senescence.
Wanglai, Hu +3 more
openaire +2 more sources
MUT-TP53: a versatile matrix for TP53 mutation verification and publication
Human Mutation, 2006Thierry, Soussi +2 more
openaire +2 more sources